Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG)

Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.

EP. 1: Overview of pLGG presentation and categorization

July 19th 2024

Key opinion leaders offer a comprehensive overview of pediatric low-grade glioma, encompassing its epidemiology, characteristic disease presentation, differentiation from adult manifestations, and impact on patients' quality of life.

EP. 2: Molecular Characterization of pLGG

July 19th 2024

Experts examine the molecular diversity of pediatric low-grade gliomas, exploring its significance for diagnostic approaches and therapeutic strategies.

EP. 3: Less Common Molecular Alterations in pLGG and Testing Recommendations

July 26th 2024

The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.

EP. 4: Standard of care for frontline treatment of non-V600E-specific pLGG tumors

July 26th 2024

The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current best practices and therapeutic approaches.

EP. 5: Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

August 2nd 2024

The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.

EP. 6: Current Treatment of Patients with NF1 pLGG

August 2nd 2024

EP. 7: Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

August 9th 2024

The panel explores the standard of care options tailored specifically for the frontline treatment of pediatric low-grade gliomas (pLGG) harboring the BRAF V600E mutation, discussing current best practices and targeted therapeutic approaches.

EP. 8: Treatment Considerations for Progressive pLGG

August 9th 2024

EP. 9: Radiation and Targeted Therapies for Progressive pLGG

August 16th 2024

The panel of medical experts examines the roles of radiation therapy and targeted therapies in the management of progressive pediatric low-grade gliomas (pLGG).

EP. 10: The Role of Tovorafenib in Treatment of Progressive pLGG

August 16th 2024

The panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.